Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | MPL | P40238 | 3/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2534593 | 0.84 | AXL (0.38) | AXLMPLPNMTTAAR1PARP1 | |
| SCHEMBL1491322 | 0.68 | ALDH1A1 (0.36) | ALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL4752477 | 0.68 | TRPA1 (0.36) | — | |
| SCHEMBL2977865 | 0.68 | CYP3A4 (0.35) | ALDH1A1POLBTDP1 | |
| SCHEMBL2979302 | 0.68 | CYP2A6 (0.35) | ALDH1A1 | |
| SCHEMBL5603316 | 0.68 | CYP1A2 (0.37) | AXLHSD11B1KIF11ALDH1A1POLB | |
| SCHEMBL5600573 | 0.67 | HSD11B1 (0.41) | MPLHSD11B1CES1 | |
| SCHEMBL5603289 | 0.65 | HSD11B1 (0.36) | AXLMPLPARP1HSD11B1KIF11 | |
| SCHEMBL29441997 | 0.61 | ALDH1A1 (0.52) | HSD11B1KIF11ALDH1A1POLBTDP1 | |
| SCHEMBL63469 | 0.61 | ALDH1A1 (0.52) | HSD11B1KIF11ALDH1A1POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200079801-A1 | TRISUBSTITUTEDSILYLBENZYLBENZIMIDAZOLES AND ANALOGUES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-03-12 | — | — | US | disclosed |
| WO-2008146064-A1 | NEW BENZOFURAN DERIVATIVES AS SELECTIVE 5HT7 RECEPTOR INHIBITORS AND PROCESS FOR THEIR PREPARATION | EGIS GYÓGYSZERGYÁR (HU) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200079801-A1 | TRISUBSTITUTEDSILYLBENZYLBENZIMIDAZOLES AND ANALOGUES | PIK3C3, DPM1, ERG28 | AXL 2077/4885MPL 4548/4885PNMT 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.